AVTX Research | Milton Maxwell

AVTX

Avalo Therapeutics, Inc.

18.82

+1.12+6.33%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

341.28M

P/E (TTM)

Basic EPS (TTM)

-13.42

Dividend Yield

Recent Filings

8-K

12/2/25Dec 2, 2025

10-Q

11/6/25Nov 6, 2025

8-K

11/6/25Nov 6, 2025

8-K

10/29/25Oct 29, 2025

8-K

AVTX-009 HS trial update

10/10/25Oct 10, 2025

Avalo Therapeutics updated its investor presentation on October 10, 2025, spotlighting AVTX-009, a high-affinity IL-1β inhibitor targeting hidradenitis suppurativa's unmet needs amid incomplete responses to anti-TNF and anti-IL-17 therapies. The Phase 2 LOTUS trial is enrolling biologic-naïve and experienced patients, with topline data due mid-2026; HS market growth to over $10B by 2035 underscores potential. Cash of $112 million extends runway into 2028. Forward-looking statements carry risks from trials and markets.

About

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CEO

Dr. Garry A. Neil M.D.

IPO

10/14/2015

Website

https://www.avalotx.com

Employees

Sector

Healthcare

Industry

Biotechnology